Severe Hypertriglyceridemia study: Solbinsiran
Official title A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
ClinicalTrials.gov ID: NCT07269210
What this study is testing
What is Solbinsiran?
An investigational subcutaneous injectable medicine being studied as a potential treatment for severe hypertriglyceridemia.
Also referred to as LY3561774.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if solbinsiran is safe and can lower triglyceride and other lipid levels compared with a placebo.
- Who it's for
- Adults who have severe hypertriglyceridemia.
- What's involved
- Participants will receive two injections under the skin (subcutaneous).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
- Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
- Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
You likely can't join if
- Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
- Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
- Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral...
- Have a history of chronic alcohol abuse within 3 years prior to screening
The study team makes the final eligibility decision.
Where it is enrolling
- Chicoutimi, Canada
- Trois-Rivières, Canada
- Vancouver, Canada
- Beijing, China
- Luoyang, China
- Xuzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicoutimi, Canada; Trois-Rivières, Canada; Vancouver, Canada; Beijing, China; Luoyang, China; Xuzhou, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.